Biocon Biologics Limited et al. vs. Regeneron Pharmaceuticals, Inc.

Explore the PTAB proceeding PGR2026-00039 filed by Biocon Biologics Limited et al. on 2026-04-02. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

PGR2026-00039

Filing Date

2026-04-02

Accorded Filing Date

2026-04-02

Institution Decision Date

2026-09-24

Last Modified Date

2026-09-24

Proceeding Type

PGR

Termination Date

2026-09-24

Trial Status

Discretionary Denial

Parties & Counsel

Petitioner

Biocon Biologics Limited et al.

Represented By

BORDER, SCOTTet al

Patent Owner / Respondent

Regeneron Pharmaceuticals, Inc.

Represented By

Berl, Davidet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 17384070

Respondent Patent Number 12168036

External Links

Espacenet

Google Patents

Respondent Inventor Kenneth S. Graham et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

31 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name Schwabe W&W, PC / Regeneron Pharmaceuticals, Inc.

Customer Number 147803

Address 1211 SW Fifth Avenue,, Suite 1800, Portland, OR, 97204, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
43184	Lance Termes	541-749-4044
48001	Thomas Triolo	914-847-1612
48921	Stephen Gaudet	914-847-7376
50370	Neil Miyamoto	914-847-7175
50437	Frank Cottingham	914-593-1116
54144	Zhongmin Guo	4089389060
54712	Kajal Chowdhury	914-418-0068
55296	Michelle Iwamoto-Fan	914-678-4255
58583	Brian Cocca	914-847-1421
58714	Ilona Gont	914-847-1304
59668	Brandon Schurter	914-847-7000
60281	Aparna Patankar	914-847-5571
61391	Yonghao Hou	914-839-2555
63401	Shing-Yi Cheng	914-847-5750
65789	Margarita Zippin	914-847-5589
65957	Lisa Flanagan	914-847-8175
67063	Mythili Markowski	202-452-7314
67881	Eileen Woo	914-847-1246
68046	Elysa Goldberg	914-847-1280
68059	David Mellman	720-391-8767
68136	Christopher Westberg	914-847-7912
70449	Haiou Qin	--
71406	Gabriele Amodeo	914-847-3578
72275	Adam Gastonguay	914-648-8609
73212	Trisha Agrawal	914-313-7694
73388	Geoffry Knudsen	919-923-4568
73446	Xiongying Tu	612-401-2690
73448	Liang Zeng Yan	914-409-6476
74751	Casey Donahoe	814-931-8622
79168	Ann Bernert	503-595-5300
80578	Dhruv Sud	314-917-1241

Proceeding Documents

118

Director Discretionary Decision: Deny RESPONSE

2026-09-24 FILING PARTY: BOARD

Download

Director Discretionary Decision: Deny RESPONSE

2026-08-06 FILING PARTY: BOARD

Download

Order: Granting Motion to Excuse Late Filing ORDER

2026-07-23 FILING PARTY: BOARD

Download

1074

EX.1074 Exhibit

2026-07-07 FILING PARTY: PETITIONER

Download

1079

EX.1079 Exhibit

2026-07-07 FILING PARTY: PETITIONER

Download

Biocon Biologics Limited et al. vs. Regeneron Pharmaceuticals, Inc.

Proceeding Overview

Parties & Counsel

Petitioner

Biocon Biologics Limited et al. Follow

Represented By

Patent Owner / Respondent

Regeneron Pharmaceuticals, Inc. Follow

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Director Discretionary Decision: Deny RESPONSE

Director Discretionary Decision: Deny RESPONSE

Order: Granting Motion to Excuse Late Filing ORDER

EX.1074 Exhibit

EX.1079 Exhibit

EX.1076 Exhibit

Petitioner's Opposition to Patent Owner's Request for Discretionary Denial of Institution RESPONSE

EX.1072 Exhibit

EX.1078 Exhibit

EX.1073 Exhibit

EX.1075 Exhibit

EX.1077 Exhibit

EX.1071 - Taneja Dec. Exhibit

ORDER Granting Petitioner’s Unopposed Motion to Withdraw and Substitute Counsel 37 C.F.R. § 42.10 ORDER

Declaration of Andrew V. Trask (June 11, 2026) (“Trask Decl.”) Exhibit

Patent Owner’s Unopposed Motion to Excuse the Late Filing of Patent Owner’s Exhibits in Support of Its Discretionary Denial Brief MOTION

U.S. Food & Drug Admin., Eylea HD® Approval Letter (August 18, 2023) (“Eylea HD® FDA Approval Letter”) Exhibit

Novartis, Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program, Novartis Media Releases (May Exhibit

Kiran Stacey et al., Regeneron: The Company That Trump Claims Cured His Covid, Financial Times (Oct. 9, 2020), https://www.ft.com/content/70672ed3-bf66-4c14-8392-076d0c503558 (“Stacey 2020a”) Exhibit

Berkeley Lovelace Jr., FDA Approves First Gene Therapy for Genetic Hearing Loss, NBC News (Apr. 23, 2026), https://www.nbcnews.com/health/health-news/fda-approves-first-gene-therapy-genetic-hearing-loss-rcna341666 (“Lovelace”) Exhibit

Eylea HD® Highlights of Prescribing Information (Oct. 2024) (“Eylea HD® Label) Exhibit

Declaration of Daniel Van Plew (June 8, 2026) (“Van Plew Decl.”) Exhibit

Manufacturing Operations: Overview, Biocon, https://www.biocon.com/businesses/generics/overview-manufacturing-operations/ (last accessed May 27, 2026) (“Biocon Manufacturing”) Exhibit

Donald Trump Remarks Transcript, Calls Contracting COVID-19 “Blessing from God” October 7, @Rev, https://www.rev.com/transcripts/donald-trump-remarks-transcript-calls-contracting-covid-19-blessing-from-god-october-7 (last accessed Mar. 19, 2026) (“2020 Transcript”) Exhibit

Philip J. Rosenfeld & David J. Browning, Editorial: Is This a 737 Max Moment for Brolucizumab?, 216 Am. J. Ophthalmology A7 (2020) (“Rosenfeld”) Exhibit

Public Trial Transcript Excerpts, Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., No. 22-cv-61 (N.D.W. Va.) Exhibit

John S.Y. Park & David R. Chow, Clinical Primer on Eylea HD: Review of the Current Data, Retina Specialist (Apr. 13, 2024), https://www.retina-specialist.com/article/clinical-primer-on-eylea-hd-review-of-the-current-data (“Park”) Exhibit

Rahul N. Khurana et al., Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration, 128 Ophthalmology 1027 (2021) (“Khurana 2021”) Exhibit

Kiran Stacey, Trump Calls Coronavirus Treatment He Received a “Cure”, Financial Times (Oct. 7, 2020), https://www.ft.com/ content/a792326c-40e7-460d-ac38-8a9b03286ea0 (“Stacey 2020b”) Exhibit

Beovu Label (2024) Exhibit

Petitioners' Updated Mandatory Notices NOTICE

Petitioners' Unopposed Motion to Withdraw and Substitute Counsel MOTION

Petitioners' Updated Power of Attorney NOTICE

Patent Owner's Discretionary Denial Brief RESPONSE

E-mail authorizing motion to withdraw Exhibit

Petitioner's Reply to Patent Owner's Opposition to Petitioner's Motion for Joinder REPLY

Patent Owner's Opposition to Petitioner's Joinder Motion OPPOSITION

Notice: Mandatory Notice NOTICE

Notice: Power of Attorney NOTICE

Notice: Notice filing date accorded NOTICE

EX.1061 - Loureiro 2017 Exhibit

EX.1019 - Cohen and Gardner Exhibit

EX.1027 - Hong 2018 Exhibit

EX.1057 - Vabysmo 2022 Label Exhibit

EX.1005 - U.S. Patent 7,608,261 (Furfine) Exhibit

EX.1054 - Eylea HD 2024 Label Exhibit

EX.1037 - Gutierrez and Ferrara Exhibit

EX.1034 - Nguyen 2009 Exhibit

Notice: Power of Attorney NOTICE

EX1070 - Alvotech Institution Decision Exhibit

EX.1039 - Stewart 2012 Exhibit

EX.1052 - Eylea 2014 Label Exhibit

EX.1002 - U.S. Patent 12,168,036 File History Part 5 Exhibit

Petition: as filed PETITION

EX.2012 WO 2016/154288 (Ingber) Exhibit

EX.1008 - 2011 Eylea® Clinical Review Exhibit

EX.1003 - Declaration of Dr. Donald Joseph D’Amico Exhibit

EX.1042 - Varma 2014 Exhibit

EX.1029 - Jin and Hwang Exhibit

EX.1018 - Celik 2015 Exhibit

EX.1026 - Ho 2014 Exhibit

EX.1016 - Brown 2015 Exhibit

EX.1015 - Awwad 2017 Exhibit

Motion: Joinder MOTION

EX.1002 - U.S. Patent 12,168,036 File History Part 7 Exhibit

Biocon Biologics Limited et al.

Regeneron Pharmaceuticals, Inc.